Solutions
You will receive an email with a link to the webinar
Join us for this webinar with Dr. Mitchell E. Horwitz, Director of the Adult Blood and Marrow Transplant Program and Professor of Medicine at the Duke University Medical Center.
Hear about the results of a phase 3 randomized study on the efficacy of omidubicel vs. standards myeloablative umbilical cord blood transplantation.
Omidubicel is an ex vivo expanded hematopoietic progenitor cell and non-expanded myeloid and lymphoid cell product that is derived from a single umbilical cord blood unit.
During this session, Dr. Horwitz reports on a phase 3 trial that evaluates the efficacy of omidubicel compared with standard umbilical cord blood transplantation.
Between January 2017 and January 2020, 125 patients ages 13 to 65 years with hematologic malignancies were randomly assigned to this study. Patients received myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease. Results from this study suggest that omidubicel may be considered as a new standard of care for adult patients for UCBT.
Register now to receive a link to the recording and slides.
Recorded Oct 23, 2018
WellSky only wants to send you the information you are interested in. Please fill out the form below to choose the emails you want to receive. We only send emails to subscribers. If you are an existing customer, you will continue to receive certain notifications.
People who choose a life of caring — and the organizations and communities they serve — deserve a special kind of support. So we help them to care smarter. Liberating them to focus on the people they serve. Providing solutions that make work flow, integrate insights, and update effortlessly.
People who choose a life of caring — and the organizations and communities they serve — deserve a special kind of support. So we help them to care smarter. Liberating them to focus on the people they serve. Providing solutions that make work flow, integrate insights, and update effortlessly.
People who choose a life of caring — and the organizations and communities they serve — deserve a special kind of support. So we help them to care smarter. Liberating them to focus on the people they serve. Providing solutions that make work flow, integrate insights, and update effortlessly.
WellSky is a technology company that delivers software and services to transform an ever-growing range of care services worldwide. Building on a history of excellence and a reputation for quality, WellSky – formerly Mediware Information Systems and Kinnser Software – empowers providers to provide exceptional care, improve operational efficiency, reduce cost, and meet the challenges of their rapidly changing industries.
People who choose a life of caring — and the organizations and communities they serve — deserve a special kind of support. So we help them to care smarter. Liberating them to focus on the people they serve. Providing solutions that make work flow, integrate insights, and update effortlessly. So they're able to anticipate — and exponentially increase — the impact of care.
People who choose a life of caring — and the organizations and communities they serve — deserve a special kind of support. So we help them to care smarter. Liberating them to focus on the people they serve. Providing solutions that make work flow, integrate insights, and update effortlessly. So they're able to anticipate — and exponentially increase — the impact of care.